FindTrial
Sign In

Efficacy of Karpoor and Ajwain inhalation in COVID-19 patients

Effects of add on Cinnamomum Camphora and Ajwain inhalation to the standard treatment on oxygen saturation in patients with COVID-19: A prospective studyathing pacer" in patients with COPD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033499
Enrollment
100
Registered
2021-05-10
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Study Inhaler: Inhaler containing Cinnamomum Camphora (1 gm) and Trachyspermum ammi (1 gm) Dose: Deep inhalation (3-4 puffs) at least every two hours during awake period, OR as frequent

Sponsors

D Y Patil University School of Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult ( >18 years) COVID-19 positive patients of either gender 2. Patients hospitalized in COVID-19 wards 3. Patients having SpO2 saturation of �90% on room air at enrolment

Exclusion criteria

Exclusion criteria: 1. Patients on mechanical ventilation 2. Patients requiring nasal oxygen >6 litres/minutes 3. Patients with respiratory disorders, bronchial asthma, or COPD 4. Existing pulmonary tuberculosis 5. Patients admitted in ICU 6. Pregnant women

Design outcomes

Primary

MeasureTime frame
Time to recovery (defined as the satisfaction of criteriaââ?¬â?¢s 1, 2 or 3 of the 8-category ordinal scale for clinical improvement)Timepoint: End of study (up to 28 days)—

Secondary

MeasureTime frame
All-cause mortalityTimepoint: End of therapy;Mean oxygen saturation (SpO2)Timepoint: Recorded on daily basis after start of study therapy till patient is hospitalized or 28 days;Patient satisfaction score on a 5-point Likert scale of 1: Dissatisfied; 2: Neither satisfied nor dissatisfied; 3: Satisfied; 4: Somewhat satisfied; 5: Extremely satisfiedTimepoint: End of therapy;Percentage of patients requiring admission in ICUTimepoint: End of therapy;Percentage of patients requiring mechanical ventilationTimepoint: End of therapy;Percentage of patients requiring remdesivirTimepoint: End of therapy;Percentage of patients requiring tocilizumab/ Itolizumab/ bevacizumabTimepoint: End of therapy;Proportion of participants experiencing Treatment-Emergent Adverse Events (TEAE)Timepoint: End of study;Total duration of hospital stays (days)Timepoint: End of therapy—

Countries

India

Contacts

Public ContactBharati Kulkarni

D Y Patil University School of Medicine

bharati.kulkarni@dypatil.edu9820554431

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026